Mid-year Review: Watertown breaks Q1 & Q2 Fundraising Record, ranks 3rd in MA for biotech according to MassBio

Mid-year Review: Watertown breaks Q1 & Q2 Fundraising Record, ranks 3rd in MA for biotech according to MassBio

Sam Ghilardi 9/1/26 Sam Ghilardi 9/1/26

Mid-year Review: Watertown breaks Q1 & Q2 Fundraising Record, ranks 3rd in MA for biotech according to MassBio

Plus Werewolf Finds a Buyer

LifeMine Closes Watertown's Largest Funding Round of 2026 and EyePoint's Phase 3 Miss

Sam Ghilardi 8/18/26 Sam Ghilardi 8/18/26

LifeMine Closes Watertown's Largest Funding Round of 2026 and EyePoint's Phase 3 Miss

Plus a flurry of clinical trial updates and quarterly reports

Sam Ghilardi 5/5/26 Sam Ghilardi 5/5/26

Watertown Journal Club - Posterpalooza

Two big conferences last month generated a flurry of posters from Watertown biotechs

Triveni's New Digs, 99 Coolidge's Tenant Bonanza, and Remix's FDA Fast Track Designation

Sam Ghilardi 3/31/26 Sam Ghilardi 3/31/26

Triveni's New Digs, 99 Coolidge's Tenant Bonanza, and Remix's FDA Fast Track Designation

Plus Addgenes' new partnership, and Neumora and Acrivon's cash flow updates

Sam Ghilardi 11/18/25 Sam Ghilardi 11/18/25

Labshares Expanding to Watertown

Neumora's Wegovy alternative, Dyno announces manufacturing pact, and more